ARCHIVES

Senate Markup Would Give NCI $985 Million, Offers Prospect That Reductions In Grants Will Be Restored

This article is from The Cancer Letter archive.

Vol. 08 No. 48 | December 10, 1982

Download PDF Visit The Full Archive

Related Articles

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

August 26, 2005

High Risk workshop Planned To Produce Monograph On Current Knowledge

October 11, 1974

LAK –IL-2 Studies Continue, Moertel Editorial Blasted

March 13, 1987

Selumetinib Displays Positive Results, 60% with Stable Disease

April 29, 2011

In Brief: FCRF Contract Hopefuls Make Oral Presentation; Jane Rowley To Deliver Karnofsky Lecture

April 10, 1987

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

November 28, 2014